Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Brugger

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Blood|November 26, 1999
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemiaE Archimbaud, O G Ottmann, J A Yin, et al.
British Journal of Cancer|March 17, 2011
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancerH J Stemmler, D diGioia, W Freier, et al.
Blood|December 3, 1998
2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cellsA Maran, C F Waller, J M Paranjape, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patientsP Viens, C Chabannon, P Pouillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II studyW Brugger, J Hirsch, F Grünebach, et al.
Leukemia|March 16, 2017
Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myelomaH Einsele, S Knop, M Vogel, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Gastroenterology|February 9, 2026
Genomic Insights Into Inflammatory Bowel Disease in United States Hispanic Participants: An Ancestry-Focused StudyAshley H Beecham, Dermot P B McGovern, Steven W Brugger, et al.
Microbiology Resource Announcements|February 7, 2024
Complete genome sequences of five <i>Ackermannviridae</i> that infect <i>Enterobacteriaceae</i> hostsEvan B Harris, Laura B Anthony, Sakhawat Ali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancerB Basu, M G Krebs, R Sundar, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Blood|November 26, 1999
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemiaE Archimbaud, O G Ottmann, J A Yin, et al.
British Journal of Cancer|March 17, 2011
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancerH J Stemmler, D diGioia, W Freier, et al.
Blood|December 3, 1998
2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cellsA Maran, C F Waller, J M Paranjape, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patientsP Viens, C Chabannon, P Pouillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II studyW Brugger, J Hirsch, F Grünebach, et al.
Leukemia|March 16, 2017
Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myelomaH Einsele, S Knop, M Vogel, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Gastroenterology|February 9, 2026
Genomic Insights Into Inflammatory Bowel Disease in United States Hispanic Participants: An Ancestry-Focused StudyAshley H Beecham, Dermot P B McGovern, Steven W Brugger, et al.
Microbiology Resource Announcements|February 7, 2024
Complete genome sequences of five <i>Ackermannviridae</i> that infect <i>Enterobacteriaceae</i> hostsEvan B Harris, Laura B Anthony, Sakhawat Ali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancerB Basu, M G Krebs, R Sundar, et al.
Pageof 12